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On page 810, [Table 4](#t4-ceor-11-083){ref-type="table"}, Drug costs column, Methotrexate, the Unit WAC was listed as \$1 however it should have been \$2.36. The updated table is as follows:

On page 817, [Table S2](#SD1-ceor-11-083){ref-type="supplementary-material"}, the monitoring costs for (**A**) csD-MARD-IR and (**B**) TNF-IR were changed. The updated table is as follows:

Supplementary material
======================

###### 

Budget impact by cost metric in years 1--5, in (**A**) csDMARD-IR, (**B**) TNF-IR populations, (**C**) combination (pooled csDMARD-IR and TNF-IR), and (**D**) monotherapy (csDMARD-IR or TNF-IR)

  Cost by metric                                               Year 1         Year 2         Year 3         Year 4         Year 5         Years 1--5
  ------------------------------------------------------------ -------------- -------------- -------------- -------------- -------------- ----------------
  **(A) csDMARD-IR**                                                                                                                      
  **DMARDs**                                                                                                                              
  Base-case                                                    \$20,254,095   \$20,824,169   \$21,474,496   \$22,205,356   \$23,026,048   \$107,784,164
  Projected                                                    \$20,226,459   \$20,764,870   \$21,378,464   \$22,066,321   \$22,836,306   \$107,272,419
  Net                                                          −\$27,636      −\$59,299      −\$96,033      −\$139,035     −\$189,742     −\$511,744
  **Administration**                                                                                                                      
  Base-case                                                    \$223,299      \$223,756      \$224,254      \$224,677      \$224,996      \$1,120,982
  Projected                                                    \$222,182      \$221,518      \$220,890      \$220,184      \$219,371      \$1,104,146
  Net                                                          −\$1,116       −\$2,238       −\$3,364       −\$4,494       −\$5,625       −\$16,836
  **Concomitant medications**                                                                                                             
  Base-case                                                    \$8,699        \$8,717        \$8,736        \$8,752        \$8,765        \$43,668
  Projected                                                    \$8,696        \$8,712        \$8,729        \$8,743        \$8,753        \$43,634
  Net                                                          −\$3           −\$5           −\$7           −\$9           −\$12          −\$35
  **Monitoring**                                                                                                                          
  Base-case                                                    \$61,176       \$61,301       \$61,438       \$61,554       \$61,641       \$307,110
  Projected                                                    \$61,321       \$61,593       \$61,876       \$62,139       \$62,373       \$309,302
  Net                                                          \$145          \$291          \$438          \$585          \$732          \$2,192
  ***Total costs***                                                                                                                       
  Base-case                                                    \$20,547,268   \$21,117,943   \$21,768,924   \$22,500,339   \$23,321,449   \$109,255,924
  Projected                                                    \$20,518,659   \$21,056,693   \$21,669,959   \$22,357,386   \$23,126,803   \$108,729,500
  Net                                                          −\$28,610      −\$61,249      −\$98,965      −\$142,953     −\$194,646     −\$526,424
  (**B**) TNF-IR                                                                                                                          
  **DMARDs**                                                                                                                              
  Base-case                                                    \$15,608,855   \$16,031,438   \$16,510,886   \$17,046,450   \$17,644,182   \$82,841,812
  Projected                                                    \$15,592,910   \$15,996,734   \$16,453,889   \$16,962,801   \$17,528,531   \$82,534,865
  Net                                                          −\$15,945      −\$34,705      −\$56,997      −\$83,649      −\$115,651     −\$306,948
  **Administration**                                                                                                                      
  Base-case                                                    \$228,199      \$228,667      \$229,176      \$229,608      \$229,934      \$1,145,585
  Projected                                                    \$227,058      \$226,380      \$225,738      \$225,016      \$224,186      \$1,128,379
  Net                                                          −\$1,141       −\$2,287       −\$3,438       −\$4,592       −\$5,748       −\$17,206
  **Concomitant medications**                                                                                                             
  Base-case                                                    \$7,206        \$7,220        \$7,236        \$7,250        \$7,260        \$36,173
  Projected                                                    \$7,204        \$7,218        \$7,233        \$7,245        \$7,254        \$35,154
  Net                                                          −\$2           −\$2           −\$3           −\$5           −\$6           −\$9
  **Monitoring**                                                                                                                          
  Base-case                                                    \$55,731       \$55,846       \$55,970       \$56,075       \$56,155       \$279,777
  Projected                                                    \$55,833       \$56,050       \$56,277       \$56,485       \$56,668       \$281,313
  Net                                                          \$102          \$204          \$307          \$410          \$513          \$1,536
  ***Total costs***                                                                                                                       
  Base-case                                                    \$15,899,992   \$16,323,171   \$16,803,268   \$17,339,384   \$17,937,532   \$84,303,347
  Projected                                                    \$15,883,006   \$16,286,381   \$16,743,137   \$17,251,548   \$17,816,639   \$83,980,711
  Net                                                          −\$16,986      −\$36,790      −\$60,131      −\$87,837      −\$120,893     −\$322,637
  (**C**) Combination therapy (pooled csDMARD-IR and TNF-IR)                                                                              
  **DMARDs**                                                                                                                              
  Base-case                                                    \$36,177,639   \$37,182,732   \$38,327,255   \$39,610,950   \$41,049,549   \$192,348,125
  Projected                                                    \$36,132,484   \$37,085,458   \$38,169,098   \$39,381,082   \$40,734,673   \$191,502,794
  Net                                                          −\$45,155      −\$97,274      −\$158,157     −\$229,868     −\$314,876     −\$845,331
  **Administration**                                                                                                                      
  Base-case                                                    \$442,973      \$443,881      \$444,869      \$445,708      \$446,340      \$2,223,771
  Projected                                                    \$440,758      \$439,442      \$438,196      \$436,794      \$435,182      \$2,190,372
  Net                                                          −\$2,215       −\$4,439       −\$6,673       −\$8,914       −\$11,159      −\$33,399
  **Concomitant medications**                                                                                                             
  Base-case                                                    \$15,932       \$15,965       \$16,000       \$16,031       \$16,053       \$79,981
  Projected                                                    \$15,929       \$15,957       \$15,989       \$16,016       \$16,035       \$79,925
  Net                                                          −\$3           −\$8           −\$11          −\$15          −\$19          −\$56
  **Monitoring**                                                                                                                          
  Base-case                                                    \$116,023      \$116,260      \$116,519      \$116,739      \$116,905      \$582,446
  Projected                                                    \$116,274      \$116,765      \$117,277      \$117,752      \$118,172      \$586,240
  Net                                                          \$252          \$504          \$758          \$1,013        \$1,262        \$3,794
  ***Total costs***                                                                                                                       
  Base-case                                                    \$36,752,567   \$37,758,838   \$38,904,643   \$40,189,428   \$41,628,848   \$195,234,324
  Projected                                                    \$36,705,445   \$37,657,622   \$38,740,560   \$39,951,644   \$41,304,062   \$194,359,332
  Net                                                          −\$47,122      −\$101,216     −\$164,083     −\$237,784     −\$324,786     −\$874,992
  **Cost by metric**                                           **Year 1**     **Year 2**     **Year 3**     **Year 4**     **Year 5**     **Years** 1--5
  (**D**) Monotherapy (csDMARD-IR or TNF-IR)                                                                                              
  **DMARDs**                                                                                                                              
  Base-case                                                    \$10,746,634   \$11,047,944   \$11,391,063   \$11,775,969   \$12,207,397   \$57,169,007
  Projected                                                    \$10,732,920   \$11,018,425   \$11,343,110   \$11,706,334   \$12,112,089   \$56,912,879
  Net                                                          −\$13,714      −\$29,518      −\$47,952      −\$69,635      −\$95,308      −\$256,127
  **Administration**                                                                                                                      
  Base-case                                                    \$132,892      \$133,164      \$133,461      \$133,712      \$133,902      \$667,131
  Projected                                                    \$132,228      \$131,833      \$131,459      \$131,038      \$130,555      \$657,112
  Net                                                          −\$664         −\$1,332       −\$2,002       −\$2,674       −\$3,348       −\$10,020
  **Concomitant medications**                                                                                                             
  Base-case                                                    \$4,780        \$4,789        \$4,800        \$4,809        \$4,816        \$23,994
  Projected                                                    \$4,779        \$4,787        \$4,797        \$4,805        \$4,810        \$23,978
  Net                                                          −\$1           −\$2           −\$3           −\$4           −\$6           −\$17
  **Monitoring**                                                                                                                          
  Base-case                                                    \$5,902        \$5,914        \$5,927        \$5,938        \$5,947        \$29,628
  Projected                                                    \$6,025        \$6,161        \$6,298        \$6,434        \$6,567        \$31,486
  Net                                                          \$123          \$247          \$371          \$496          \$621          \$1,858
  ***Total costs***                                                                                                                       
  Base-case                                                    \$10,890,208   \$11,191,811   \$11,535,251   \$11,920,429   \$12,352,061   \$57,889,760
  Projected                                                    \$10,875,951   \$11,161,206   \$11,485,664   \$11,848,611   \$12,254,022   \$57,625,454
  Net                                                          −\$14,256      −\$30,605      −\$49,586      −\$71,818      −\$98,040      −\$264,306

**Abbreviations:** csDMARD, conventional synthetic disease-modifying antirheumatic drug; DMARD, disease-modifying antirheumatic drug; IR, inadequate response; TNF, tumor necrosis factor inhibitor.

###### 

Drug cost summary

  Drug costs                   Dose       Package size     WAC        Unit WAC   Annual cost[a](#tfn1-ceor-11-083){ref-type="table-fn"}   Annual price increase[b](#tfn2-ceor-11-083){ref-type="table-fn"}   Net WAC with ICER specified discounts[c](#tfn3-ceor-11-083){ref-type="table-fn"}
  ---------------------------- ---------- ---------------- ---------- ---------- -------------------------------------------------------- ------------------------------------------------------------------ ----------------------------------------------------------------------------------
                                                                                                                                                                                                             
  **Non-TNFi biologics**                                                                                                                                                                                     
  Abatacept (SC)               125.0 mg   4 syringes       \$4,131    \$1,033    \$57,359                                                 13.5%                                                              \$2892
  Abatacept (IV)               250.0 mg   1 vial           \$1,046    \$1,046    \$49,906                                                 13.5%                                                              \$732
  Rituximab (IV)               100.0 mg   1 vial           \$835      \$835      \$50,863                                                 5.0%                                                               \$710
  Sarilumab (SC)               150.0 mg   2 syringes       \$3,159    \$1,580    \$43,317                                                 5.3%                                                               \$2,527
  Sarilumab (SC)               200.0 mg   2 syringes       \$3,159    \$1,580    \$41,208                                                 5.3%                                                               \$2,527
  Tocilizumab (SC)             162.0 mg   1 syringe        \$985      \$985      \$40,117                                                 8.4%                                                               \$788
  Tocilizumab (IV)             80.0 mg    1 vial           \$417      \$417      \$39,038                                                 6.3%                                                               \$333
  **TNFi biologics**                                                                                                                                                                                         
  Adalimumab (SC)              40.0 mg    6 pens           \$14,616   \$2,436    \$73,542                                                 14.9%                                                              \$10,231
  Certolizumab pegol (SC)      200.0 mg   3 syringe kits   \$12,132   \$4,044    \$68,232                                                 9.9%                                                               \$8,493
  Etanercept (SC)              50.0 mg    4 syringes       \$4,872    \$1,218    \$59,953                                                 16.4%                                                              \$3,410
  Golimumab (SC)               50.0 mg    1 syringe        \$4,520    \$4,520    \$68,955                                                 14.5%                                                              \$3,164
  Golimumab (IV)               50.0 mg    1 vial           \$1,734    \$1,734    \$59,952                                                 14.5%                                                              \$1,213
  Infliximab (IV)              100.0 mg   1 vial           \$1,168    \$1,168    \$37,228                                                 8.3%                                                               \$817
  Infliximab (IV) biosimilar   100.0 mg   1 vial           \$889      \$889      \$28,332                                                 8.3%                                                               \$622
  **JAK inhibitors**                                                                                                                                                                                         
  Tofacitinib (Oral)           5.0 mg     60 tablets       \$4,099    \$63       \$46,213                                                 15.5%                                                              \$3,891
  **csDMARDs**                                                                                                                                                                                               
  Methotrexate                 2.5 mg     100 tablets      \$236      \$2.36     \$1,139                                                  0.0%                                                               Not applicable
  Concomitant medication:                                                                                                                                                                                    
  Prednisone                   10.0 mg    1 tablet         \$0.19     \$0.19     \$69                                                     0.0%                                                               Not applicable

**Notes:** Assuming full compliance, no fees, discounts or any patient out of pocket contributions.

Based on the compound annual growth rate for drug prices between January 2013 to January 2016.^37^

Discounts**:** TNFi: 30%, CD-20 directed cytolytic antibody: 15%, T-cell inhibitors: 30%, IL-6 inhibitors: 20%, JAK inhibitors: 5%.

**Abbreviations:** csDMARD, conventional synthetic disease-modifying antirheumatic drug; IV, intravenous; JAK, janus kinase; SC, subcutaneous; TNFi, tumor necrosis factor inhibitor; WAC, wholesale acquisition cost.
